Collectively, our results suggest that NCKX2 represents a new potential target to be investigated in the neuroprotective mechanisms mediated by ischemic preconditioning and support the idea that the development of new compounds able to activate NCKX2 might be a reasonable strategy for therapeutic intervention during cerebral ischemia. This evidence concerns the gene SLC24A2 and brain ischemia.